Modified hemoglobin blood substitutes: present status and future perspectives

Biotechnology Annual Review

Volumn 4, Issue C, 1998, Pages 75-112

  Chang, T M S ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD SUBSTITUTE; CROSS LINKING REAGENT; HEMOGLOBIN; RECOMBINANT PROTEIN;

ANIMAL; BIOTECHNOLOGY; BLOOD TRANSFUSION; CATTLE; CHEMISTRY; HUMAN; METHODOLOGY; REVIEW;

ANIMALS; BIOTECHNOLOGY; BLOOD SUBSTITUTES; BLOOD TRANSFUSION; CATTLE; CROSS-LINKING REAGENTS; HEMOGLOBINS; HUMANS; RECOMBINANT PROTEINS;

EID: 0032246622     PISSN: 13872656     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1387-2656(08)70068-1     Document Type: Article

References (162)

1. Perutz MF. Stereochemical mechanism of oxygen transport by hemoglobin. Proc R Soc Lond B 208 (1980) 135
2. Amberson WR. Blood substitute. Biol Rev 12 (1937) 48
3. Rabiner S.F., Helbert J.R., Lopas H., and Friedman LH. Evaluation of stroma free hemoglobin solution as a plasma expander. J Exp Med 126 (1967) 1127
4. Moss G.S., DeWoskin R., Rosen A.L., Levine H., and Palani CK. Transport of oxygen and carbon dioxide by hemoglobin-saline solution in the red cell-free primate. Surg Gynecol Obstet 142 (1976) 357
5. Savitsky J.P., Doozi J., Black J., and Arnold JD. A clinical safety trial of stroma free hemoglobin. Clin PharmTher 23 (1978) 73
6. Chang TMS. Past, present and future perspectives on the 40th anniversary of hemoglobin-based red blood cell substitutes. Artif Cell Blood Subst Immobil Biotechnol Int J 24 (1996) ix-xxiv
7. Chang TMS. Blood Substitutes: Principles, Methods, Products and Clinical Trials 1 (1997), Karger, Basel
8. Chang TMS. Hemoglobin corpuscles. Report of a research project of B.Sc. Honours Physiology, McGill University Medical Library, Mclntyre Building, McGill University, 1957; 1--25 (reprinted in "30th Anniversary in Artificial Red Blood Cell Research" Biomaterials. Artificial Cells and Artificiall Organs 16 (1988) 1-9
9. Chang TMS. Semipermeable microcapsules. Science 146 3643 (1964) 524
10. Chang TMS. Ph.D. Thesis, McGill University, 1965.
11. Chang T.M.S., Macintosh F.C., and Mason SG. Semipermeable aqueous microcapsules: I. Preparation and properties. Can J Physiol Pharmacol 44 (1966) 115-128
12. Chang T.M.S., Macintosh F.C., and Mason SG. Encapsulated hydrophilic compositions and methods of making them. Can Patent 873 (1971) 815
13. Chang TMS. Artificial Cells. Monograph (1972), Charles C.Thomas, Springfield, IL
14. Chang T.M.S., and Poznansky MJ. Semipermeable microcapsules containing catalase for enzyme replacement in acatalsaemic mice. Nature 218 5138 (1968) 242-245
15. Chang TMS, Macintosh FC. Semipermeable Aqueous Microcapsules. Proceedings of the XIII International Congress of Physiological Sciences, Tokyo, Japan, 1965.
16. Chang T.M.S., Johnson L.J., and Ransome OJ. Semipermeable aqueous microcapsules: IV. Nonthrom-bogenic microcapsules with heparin-complexed membranes. Can J Physiol Pharmacol 45 (1967) 705-715
17. Chang TMS. Nonthrombogenic Microcapsules: US Patent 3 (1970) 522-546
18. Chang TMS. Lipid-coated spherical ultrathin membranes of polymer of cross- linked protein as possible cell membrane models. Fed Proc Am Soc Exp Biol 28 (1969) 461 (Abstract).
19. +-ATPase into the membranes of semipermeable microcapsules. J Memb Sci 6 (1980) 329-338
20. Chang TMS. Microencapsulation of enzymes and biologicals. Meth Enzymol XLIV (1976) 201-217
21. In: Chang T.M.S. (Ed). Biomedical Applications of Immobilized Enzymes and Proteins: Volumes I and II (1977), Plenum Publishing Corp., New York
22. Chang T.M.S., Yu Y.T., and Grunwald J. Artificial cells immobilized multienzyme systems and cofac-tors. Enzyme Eng 6 (1982) 451-561
23. Chang TMS. Artificial cells with cofactor regenerating multienzyme systems. Meth Enzymol 112 (1985) 195-203
24. Djordjevich L., and Miller IF. Synthetic erythrocytes from lipid encapsulated hemoglobin. Exp Hematol 8 (1980) 584
25. Chang TMS. Stabilization of enzyme by microencapsulation with a concentrated protein solution or by crosslinking with glutaraldehyde. Biochem Biophys Res Com 44 (1971) 1531-1533
26. Payne JW. Glutaraldehyde crosslinked protein to form soluble molecular weight markers. Biochem J 135 (1973) 866-873
27. Dudziak R., and Bonhard K. The development of hemoglobin preparations for various indications. Anesthesist 29 (1980) 181
28. Sehgal L.R., Rosen A.L., Gould S.A., Sehgal H.L., Dalton L., Mayoral J., and Moss GS. In vitro and in vivo characteristics of polymerized pyridoxalated hemoglobin solution. Fed Proc 39 (1980) 2383
29. Chang TMS. Artificial red blood cells. Trans Am Soc Artif Int Organs 26 (1980) 354-357
30. Keipert P.E., Minkowitz J., and Chang TMS. Cross-linked stroma-free polyhemoglobin as a potential blood substitute. Int J Artif Organs 5 6 (1982) 383
31. Benesch R., Benesch R.E., Yung S., and Edalji R. Hemoglobin covalently bridged across the polyphos-phate binding site. Biochem Biophys Res Commun 63 (1975) 1123
32. Gould S.A., and Moss GS. Clinical development of human polymerized hemoglobin as a blood substitute. World J Surg 20 (1996) 1200-1207
33. Feola M., Gonzalez H., Canizaro P.C., and Bingham D. Development of bovine stroma-free hemoglobin solution as a blood substitute. Surg Gynecol Obstet 157 (1983) 399
34. Hughes Jr. G.S., Antal E.J., Locker P.K., Francom S.F., Adams W.J., and Jacobs EE. Physiology and phar-macokinetics of a novel hemoglobin-based oxygen carrier in humans. Crit Care Med 24 (1996) 756-764
35. Hsia JC. Raffinose polymerized hemoglobin as red blood cell substitute. Biomater Artif Cell Immobil Biotechnol 19 (1991) 402
36. Keipert P.E., and Chang TMS. Pyridoxalated-polyhemoglobin solution: A low viscosity oxygen-delivering blood replacement fluid with normal oncotic pressure and long- term storage feasibility. Biomater Artif Cell Artif Organ 16 (1988) 185-196
37. Bunn H.F., and Jandl JH. The renal handling of hemoglobin. Trans Assoc Am Phys 81 (1968) 147
38. Mok W., Chen D.E., and Mazur A. Covalent linkage of subunits of hemoglobin. Fed Proc 34 (1975) 1458
39. Walder J.A., Zaugg R.H., Walder R.Y., Steele J.M., and Klotz IM. Diaspirins that cross-link alpha chains of hemoglobin: Bis(3,5-dibromosalicyl) succinate and bis(3,5-dibormosalicyl)fumarate. Biochemistry 18 (1979) 4265-4270
40. Bucci E., Razynska A., Kwansa H., Matheson-Urbaitis B., O'Hearne M., Ulatowski J.A., and Koehler RC. Production and characteristics of an infusible oxygen-carrying fluid based on hemoglobin intramolecualrly cross-linked with sebacic acid. J Lab Clin Med 128 (1996) 146-153
41. Kluger R., Jones R.T., and Shih DT. Crosslinking hemoglbin by design: lessons from using molecular clamps. Artif Cell Blood Subst Immobil Biotechnol 22 (1994) 415-428
42. Hoffman S.J., Looker D.L., Roehrich J.M., et al. Expression of fully functional tetrameric human hemoglobin in escherichia coli. Proc Natl Acad Sci USA 87 (1990) 8521-8525
43. Looker D., Abbott-Brown D., Cozart P., et al. A human recombinant hemoglobin designed for use as a blood substitute. Nature 356 (1992) 258-260
44. Shoemaker S., Stetler G., Looker D., Bates-Hill R., and Abbott-Brown D. Recombinant human hemoglobin has been engineered to decrease toxicity and improve efficacy. Biomater Artif Cell Immobil Biotechnol 19 (1991) 484-489
45. Shoemaker S., Gerber M., Evans G., Paik L., and Scoggin C. Initial clinical. Experience with a rationally designed genetically engineered recombinant human hemoglobin. Artif Cells Blood Subst Immobil Biotechnol Int J 22 (1994) 457-465
46. Olson J.S., Eich R.F., Smith L.P., Warren J.J., and Knowles BC. Protein engineering strategies for designing more stable hemoglobin-based blood substitutes. Artif Cell Blood Subst Immobil Biotechnol Int J 25 (1997) 227-241
47. O'Donnell J.K., Swanson M., Pilder S., Martin M., Hoover K., Huntress V., Karet C., Pinkert C., Lago W., and Logan J. Production of human hemoglobin in transgenic swine. Biomater Artif Cell Immobil Biotechnol 20 (1992) 149
48. Tarn S.C., and Blumenstein IWong J.T. Dextran hemoglobin. Proc Natl Acad USA 73 (1976) 2128
49. Wong JT. Rightshifted dextran-hemoglobin as blood substitute. Biomater Artif Cell Artif Organ 16 (1988) 237-245
50. Agisaka K., and Iwashita Y. Modification of human hemoglobin with polyethylene glycol: A new candidate for blood substitute. Biochem Biophys Res Commun 97 (1980) 1076
51. Iwashita Y. Relationship between chemical properties and biological properties of pyridoxalated hemoglobin-polyoxyethylene. Biomater Artif Cell Immobil Biotechnol 20 (1992) 299-308
52. Shum K.L., Leon A., Viau A.T., Pilon D., Nucci M., and Shorr RGL. The physiological and histopatho-logical response of dogs to exchange transfusion with polyethylene glycol-modified bovine hemoglobin (PEG-Hb). Artific Cell Blood Subst Immobil Biotechnol Int J 24 (1996) 655-683
53. Keipert P.E., and Chang TMS. Pyridoxalated polyhemoglobin as a blood substitute for resuscitation of lethal hemorrhagic shock in conscious rats. Biomater Med Dev Artif Organ 13 (1985) 1-15
54. Chang T.M.S., and Varma R. Effect of a single replacement of Ringer lactate, 7% albumin, hypertonic saline/dextran, stroma-free hemoglobin, o-raffinose polyhemoglobin, or whole blood, on the long term survival of fully conscious rats with lethal hemorrhagic shock after 67% acute blood loss. Biomater Artif Cell Immobil Biotechnol 20 (1992) 503-510
55. Chang T.M.S., and Varma R. Effects of Ringer lactate, albumin, stroma-free hemoglobin, o-raffinose polyhemoglobin, and whole blood on lethal hemorrhagic shock in rats. Biomater Artif Cell Immobil Biotechnol 19 (1991) 368-571
56. Chang T.M.S., and Varma R. Assessment of blood substitutes: I. efficacy studies in anesthetized and conscious rats with loss of 1/3, 1/2 and 2/3 blood volume. Artif Cell Blood Subst Immbol Biotechnol Int J 22 (1994) 159-170
57. Hess J.R., MacDonald V.W., and Winslow RM. Dehydration and shock: An animal model of hemorrhagic and resuscitation of battlefield injury. Biomater Artif Cell Immobil Biotechnol 20 (1992) 499-502
58. Dunlap E., Farrell L., Nigro C., Estep T., Marchand G., and Burhop K. Resuscitation with diaspirin crosslinked hemoglobin in a pig model of hemorrhagic shock. Artif Cell Blood Subst Immobil Biotechnol Int J 23 (1995) 39-61
59. TM): More effective than lactated Ringer's solution in restoring central venous oxygen saturation after hemorrhagic shock in rats. Artif Cell Blood Subst Immobil Biotechnol Int J 24 (1996) 197-200
60. Schultz S.C., Powell C.C., Burris D.G., et al. The efficacy of diaspirin crosslinked hemoglobin solution resuscitation in a model uncontrolled haemorrhage. J Trauma 37 (1994) 408-412
61. Malcolm D., Kissinger D., and Garrioch M. Diaspirin cross-linked hemoglobin solution as a resusci-tative fluid following severe hemorrhage in the rat. Biomater Artif Cell Immobil Biotechnol 20 (1992) 495-498
62. Matsushita M., Yabuki A., Malchesky P.S., Harasaki H., and Nose Y. In vivo evaluation of a pyridoxa-lated-hemoglobin-poloxyethylene conjugate. Bimoater Artif Cell Artif Organs 16 (1988) 247-260
63. Nho K., Linberg R., Johnson M., Gilbert C., and Shorr R. PEG-Hemoglobin: An efficient oxygen-delivery system in the rat exchange transfusion and hypovo lemic shock models. Artif Cell Blood Subst Immobil Biotechnol 22 (1996) 795-803
64. DeVenuto F., and Zegna AI. Blood exchange with pyridoxalated-polymerized hemoglobin. Surg Gynecol Obstet 155 (1982) 342
65. Keipert P., and Chang TMS. In-vivo effects of total and partial isovolemic exchange transfusion in fully conscious rats using pyridoxalated polyhemoglobin solution as a colloidal oxygen-delivery blood substitute. Vox Sanguinis 53 (1987) 7-14
66. Agishi T., Funakoshi Y., Honda H., Yamagata K., Kobayashi M., and Takahashi M. (Pyridoxalated hemoglobin) --- (Polyoxyethylene) conjugate solution as blood substitute for normothermic whole body rinse-out. Biomater Artif Cell Artif Organ 16 (1988) 261-270
67. Agishi T., Sonda K., Nakajima I., Fuchinoue S., Honda H., Uga H., Liu H., Teraoka S., and Ota K. Modified hemoglobin solution as possible perfusate relevant to organ transplantation. Biomater Artif Cell Immobil Biotechnol 20 (1992) 539-544
68. Sekiguchi S. Studies on the quality control of stroma free hemoglobin. Biomater Artif Cell Immobil Biotechnol 20 (1992) 407-414
69. Feola M., Simoni J., Rue Tran D.V.M., and Canizaro PC. Mechanisms of toxicity of hemoglobin solutions. Biomater Artif Cell Artif Organ 16 (1988) 217-226
70. Feola M., and Simoni J. Biocompatibility of hemoglobin solutions: The effects of contaminants, hemoglobin and hemoglobin derivatives. J Biomater Artif Cell Immobil Biotechnol 19 2 (1991) 382
71. Biessels P.T.M., Berbers G., Breeders G.C.J.M., Landsvater R., Huisman J., Bleeker W.K., and Bakker JC. Detection of membrane fragments in hemoglobin solutions. Biomater Artif Cell Immobil Biotechnol 20 (1992) 439-442
72. Sekiguchi S., Ito K., Kobayash M., Ototake N., Kosuda M., Kwon K.W., and Ikeda H. Preparation of virus-free pyridoxalated hemoglobin from the blood of HBV or HTLV-I healthy carriers. Biomater Artif Cell Artif Organ 16 (1988) 113-121
73. Chang TMS. Modified hemoglobin: Endotoxin and safety studies. Biomater Artif Cell Artif Organ 18 (1990) vii-viii
74. Levin J., Noth R.I., Kaca W., Yoshida M., and Su D. Hemoglobin-endotoxin interactions. In: Winslow R.M., Vandegriff K.D., and Intaglietta M. (Eds). Blood Substitutes: New Challenges (1996), Birkhäuser, Boston 185-202
75. Fratantoni JC. Points to consider in the safety evaluation of hemoglobin based oxygen carriers. Transfusion 31 (1991) 369-371
76. Chang TMS. Safety studies of modified hemoglobin as oxygen carrying blood substitute. Hema-tol Pathol 7 (1993) 47-52
77. Greenburg A.G., and Kim HW. Evaluating new red cell substitutes: A critical analysis of toxicity models. J Biomater Artif Cell Immobil Biotechnol 20 (1992) 575-581
78. Hughes G.S., Francom S.F., Antal E.J., et al. Hematologic effects of a novel hemoglobin-based oxygen carrier in normal male and female subjects. J Lab Clin 126 (1995) 444-451
79. Ning J., and Chang TMS. Effects of stoma-free Hb and polyhemoglobin on complement, activation blood cell counts and coagulation factors in rats. J Biomater Artif Cell Artif Organ 16 (1988) 651-652
80. Lalla F.R., Ning J., and Chang TMS. Effects of pyridoxalated polyhemoglobin and stroma-free hemoglobin on ADP-induced platelet aggregation. Biomater Artif Cell Artif Organ 17 (1989) 271-290
81. Ning J., and Chang TMS. Effects of homologous and heterologous stroma-free hemoglobin and poly-hemoglobin on complement activation, leukocytes and platelets. J Biomater Artif Cell Artif Organ 18 (1990) 219-233
82. Ning J., and Chang TMS. In-vivo effects of stroma-free hemoglobin and polyhemoglobin on coagulation factors in rats. Int J Artif Organ 13 8 (1990) 509-516
83. Hertzman C.M., Keipert P.E., and Chang TMS. Serum antibody titers in rats receiving repeated small subcutaneous injections of hemoglobin or poly-hemoglobin: a preliminary report. Int J Artif Organs 9 (1986) 179-182
84. Chang T.M.S., and Varma R. Pyridoxalated heterogenous and homologous polyhemoglobin and hemoglobin: systemic effects of replacement transfusion in rats previously received immunising doses. Biomater Artif Cell Artif Organ 15 (1987) 443-452
85. Chang T.M.S., and Varma R. Immunological and systemic effects of transfusions in rats using pyridoxalated hemoglobin and polyhemoglobin from hemologous and heterogenous sources. Biomater Artif Cell Artif Organ 16 (1988) 205-215
86. Chang T.M.S., Lister C., Nishiya T., and Varma R. Effects of different methods of administration and effects of modifications by microencapsulation, cross-linkage or PEG conjugation on the immunological effects of homologous and heterologous hemoglobin. J Biomater Artif Cell Immobil Biotechnol 20 (1992) 611-618
87. Estep T.N., Gonder J., Bornstein I., Young S., and Johnson RC. Immunogenicity of diaspirin cross-linked hemoglobin solutions. J Biomater Artif Cell Immobil Biotechnol 20 (1992) 603-610
88. Bleeker W.K., Zappeij L.M., den Boer P.J., Agterberg J.A., Rigter G.M.M., and Bakker JC. Evaluation of the immunogenicity of polymerized hemoglobin solutions in a rabbit model. Artif Cell Blood Subst Immobil Biotechnol Int J 23 (1995) 461-468
89. Vogel W.M., Leiberthal C.S., Apstein C.S., Levinsky N., and Valeri CR. Effects of stroma-free hemoglobin solutions on isolated perfused rabbit hearts and isolated perfused rat kidneys. J Biomater Artif Cell Artif Organ 16 (1988) 227-236
90. Intaglietta M., Johnson P.C., and Winslow RM. Microvascular and tissue oxygen distribution. Cardio-vasc Res 32 (1996) 632-643
91. Ulatowski J.A., Koehler R.C., Nishikawa T., Traystman R.J., Razynska A., Kwansa H., Urbaitis B., and Bucci E. Role of nitric oxide scavenging in peripheral vasoconstrictor response to crosslinked hemoglobin. Artif cell Blood Subst Immobil Biotechnol Int J 23 (1995) 263-269
92. Kim H.W., and Greenburg AG. Ferrous hemoglobin scavenging of endothelium derived nitric oxide is a principal mechanism for hemoglobin mediated vasoactivities in isolated rat thoracic aorta transfusion. Artif Cell Blood Subst Immobil Biotechnol Int J 25 (1997) 121-134
93. Marks D.H., Patressi J., and Chaudry IT. Effects of pyridoxalated stabilized stroma-free hemoglobin solution on the clearance of intravascular lipid by the reticuloendothelial system. Circ Shock 16 (1985) 165-172
94. Anderson P.J., Ning J., and Biro GP. Clearance of differentially labelled infused hemoglobin and polymerized hemoglobin from dog plasma and accumulation in urine and selected tissues. Biomater Artif Cell Immobil Biotechnol 20 (1992) 781-788
95. Keipert P.E., Verosky M., and Triner L. Metabolism, distribution, and excretion of HbXL: A non-dissociating interdimerically crosslinked hemoglobin with exceptional oxygen offloading capability. Biomater Artif Cell Artif Organ 16 (1988) 643-645
96. Dittmer J., Prusty S., Ichikura T., Pivacek L., Giorgio A., and Valeri CR. Intravascular retention and distribution of DBBF crosslinked stroma-free hemoglobin in the mouse. Biomater Artif Cell Immobil Biotechnol 20 (1992) 751-756
97. Chang T.M.S., and Lister C. A screening test of modified hemoglobin blood substitute before clinical use in patients --- based on complement activation of human plasma. Biomater Artif Cell Artif Organ 18 5 (1990) 693-702
98. Chang T.M.S., and Lister C. An in vitro screening test for modified hemoglobin to bridge the gap between animal safety studies and clinical use in patients. Biomater Artif Cell Immobil Biotechnol 20 (1992) 171-180
99. Chang TMS, Lister CW Screening Test for Modified Hemoglobin Blood Substitute Before Use in Human. US Patent No. 5,200,323, April 6, 1993.
100. Chang T.M.S., and Lister CW. Use of finger-prick human blood samples as a more convenient way for in vitro screening of modified hemoglobin blood substitutes for complement activation: a preliminary report. Biomater Artif Cell Immobil Biotechnol 21 (1993) 685-690
101. Chang T.M.S., and Lister C. Assessment of blood substitutes: II. In vitro complement activation of human plasma and blood for safety studies in research, development, industrial production and preclinical analysis. Artif Cell Blood Subst Immobil Biotechnol Int J 22 (1994) 159-170
102. Gould S.A., Sehgal L.R., Shehgal H.L., Dewoskin R., and Moss GS. Human polymerization hemoglobin. In: Chang T.M.S. (Ed). Blood Substitutes 2 (1998), Karger, Basel 12-38
103. Gould S.A., Sehgal L.R., Sehgal H.L., and Moss GS. The development of hemoglobin solutions as red cell substitutes: hemoglobin solutions. Transf Sci 16 (1995) 5-17
104. Pearce L.B., and Gawryl MS. Overview of biopure's HBOCs. In: Chang T.M.S. (Ed). Blood Substitutes 2 (1998), Karger, Basel 82-100
105. Adamson J.G., Moore C., and Hemolink M. In: Chang T.M.S. (Ed). Blood Substitutes 2 (1998), Karger, Basel 62-81
106. Burhop K.E., Farrell L., Nigro C., Tan D., and Estep T. Effects of intravenous infusions of diaspririn cross-linked hemoglobin (DCLHb) on sheep. Biomater Artif Cell Immobil Biotechnol 20 (1992) 581-586
107. Farmer M.C., Ebeling A., Marshall T., Hauck W., Sun C.S., White E., and Long Z. Validation of virus inactivation by heat treatment in the manufacture of diaspirin crosslinked hemoglobin. J Biomater Artif Cell Immobil Biotechnol 20 (1992) 429-434
108. Gulati A., Sharma A.C., and Singh G. Role of endothelin in the cardiovascular effects of disapirin crosslinked and stroma reduced hemoglobin. Crit Care Med 24 (1996) 137-147
109. Kumar A., Sen A.P., Saxena P.R., and Gulati A. Resuscitation with diaspirin crosslinked hemoglobin increases cerebral and renal blood perfusion in hemorrhaged rats. Artif Cell Blood Subst Immobil Biotechnol Int J 25 (1997) 85-94
110. Nelson DJ. Blood and HemAssist™ (DCLHb). In: Chang T.M.S. (Ed). Blood Substitutes 2 (1998), Karger, Basel 39-61
111. Winslow RM. Blood substitutes in development. Exp Opin Invest 5 (1996) 1443-1452
112. Caspirin, speaker, VI International Symposium on Blood Substitutes, 1996, Montreal.
113. Shorr R.G., Viau A.T., and Abuchowski A. Phase 1B safety evaluation of PEG hemoglobin as an adjuvant to radiation therapy in human cancer patients. Artif Cell Blood Subst Immobil Biotechnol Int J 24 (1996) 407 (Abstract)
114. Chang TMS. Efficacy of rbc substitutes. Artif Cell Blood Subst Immobil Biotechnol 22 (1994) ii-iii
115. Zuck TF. Difficulties in demonstrating efficacy of blood substitutes. Artif Cell Blood Subst Immobil Biotechnol (Guest editor: R. Winslow) 22 (1994) 45-954
116. Fratantoni JC. Points to consider on efficacy evaluation of hemoglobin and perfluorocarbon based oxygen carriers. Transfusion 34 (1994) 712-713
117. In: Winslow R.M., Vandegriff M., and Intaglietta M. (Eds). Blood Substitutes: New Challenges (1996), Birkhäuser, Boston
118. Chang TMS. Recent and future developments of modified hemoglobin and microencapsulated hemoglobin as red blood cell substitutes. Artif Cell Blood Subst Immobil Biotechnol Int J 25 (1997) 1-24
119. Jia L., Bonaventura C., Bonaventrua J., and Stamler JS. S-nitrosohemoglobin: a dynamic activity of blood involved in vascular control. Nature 380 (1996) 221-226
120. Stamler J.S., Jia L., Eu J.P., McMahon T.J., Demchenko I.T., Bonaventura J., Gernert K., and Piantadosi CA. Blood flow regulation by S-nitrosohemoglobin in the physiological oxygen gradient. Science 276 (1997) 2034-2037
121. Faassen A., Sundby S.R., Panter S.S., Condie R.M., and Hedlund BE. Hemoglobin: lifesaver and an oxi-dant. How to tip the balance. Biomater Artif Cell Artif Organ 16 (1988) 93-104
122. Alayash A.I., Brockner Ryan B.A., and Fratantoni JC. Hemoglobin-based oxygen carriers: structural alterations that affect free radical formation. Biomater Artif Cell Immobil Biotechnol 20 (1992) 277-282
123. Hsia CJC.Abstract volume for VI International Symposium on Blood Substitutes. Artif Cell Blood Subst Immobil Biotechnol Int J 4 1996 (24): 352.
124. Simoni J., Simoni G., Lox C.D., Prien S.D., and Shires GT. Modified hemoglobin solution with desired pharmacological properties does not activate nuclear transcription factor NF-kappa B in human vascular endothelial cells. Artif Cell Blood Subst Immobil Biotechnol Int J 25 (1997) 193-210
125. Lemon DD, Dohertym DH, Curry SR, Mathews AJ, Doyle MP, Fattor TJ, Olson JS.Abstract volume for VI International Symposium on Blood Substitutes. Artif Cell Immobil Biotechnol Int J 4(24) 1996:378.
126. DAgnillo F., and Chang TMS. Cross-linked hemoglobin-superoxide dismutase-catalase scavenges oxygen-derived free radicals and prevents methemoglobin formation and iron release. Biomater Artif Cell Immobil Biotechnol 21 (1993) 609-622
127. Chang T.M.S., and DAgnillo F. Crosslinked hemoglobin-superoxide dismutase-catalase. In: Chang T.M.S. (Ed). Blood Substitutes 2 (1998), Karger, Basel 178-196
128. DAgnillo F, Chang TMS. Modified hemoglobin blood substitute from cross-linked hemoglobin-superoxide dismutase-catalase. USA Patent 5,606,025, 1997.
129. DAgnillo F., and Chang TMS. Reduction of hydroxyl radical generation in a rat hindlimb model of ishemia-reperfusion injury using crosslinked hemoglobin-superoxide dismutase-catalase. Artif Cell Blood Subst Immobil Biotechnol Int J 25 (1997) 163-180
130. Quebec E.A., and Chang TMS. Superoxide dismutase and catalase cross-linked to polyhemoglobin reduces methemoglobin formation in vitro. Artif Cell Blood Subst Immobil Biotechnol Int J 23 (1995) 693-705
131. Quebec EA, Chang TMS.Abstract volume for VI International Symposium on Blood Substitutes. Artif Cell Blood Subst Immobil Biotechnol Int J 4(24) 1996: 408.
132. Razack S., DAgnillo F., and Chang TMS. Crosslinked hemoglobin-superoxide dismutase-catalase scavenges free radicals in a rat model of intestinal ischemia-reperfusion injury. Artif Cell Blood Subst Immobil Biotechnol Int J 25 (1997) 181-192
133. Gaber B.P., and Farmer MC. Encapsulation of hemoglobin in phospholipid vesicles: preparation and properties of a red blood cell surrogate. Prog Clin Biol Res 165 (1984) 179-190
134. Hunt A.C., Burnette R.R., MacGregor R.D., et al. Neohemocytes. Science 230 (1985) 1-165
135. Farmer M.C., Rudolph A.S., Vandegriff K.D., Havre M.D., Bayne S.A., and Johnson SA. Lipsome-encap-sulated hemoglobin: oxygen binding properties and respiratory function. J Biomater Artif Cell Artif Organ 16 (1988) 289-299
136. Beach M.C., Morley J., Spiryda L., and Weinstock SB. Effects of liposome encapsulated hemoglobin on the reticuloendothelial system. Biomater Artif Cell Artif Organ 16 (1988) 635-636
137. Rudolph AS. Encapsulated hemolgobin: current issues and future goals. Artif Cell Blood Subst Immobil Biotechnol Int J 22 (1994) 347-360
138. Rudolph AS. Encapsulation of hemoglobin in liposomes. In: Winslow R.M., Vandergriff K.D., and Intaglietta M. (Eds). Blood Substitutes: Physiological Basis of Efficacy (1995), Bikhäuser, Boston
139. Phillips W.T., Rudolph A.S., and Klipper R. Biodistribution studies of liposome encapsulated hemoglobin (LEH) studied with a newly developed 99m-technetium liposome label. Biomater Artif Cell Immobil Biotechnol 20 (1992) 757-760
140. Rollwagen F.M., Gafney W.C., Pacheo N.D., Davis T.A., Hickey T.M., Nielson T.B., and Rudolph AS. Multiple responses to admistration of liposome-encapsulaed hemoglobin (LEH): Effects on hema-topoiesis and serum IL-6 levels. Exp Hematol 24 (1996) 429-436
141. Cliff R.O., Kwasiborski V., and Rudolph AS. A comparative study of the accurate measurement of endotoxin in liposome encapsulated hemoglobin. Artif Cell Blood Subst Immobil Biotechnol Int J 23 (1995) 331-336
142. Rudolph A.S., and Phillips WT. Liposotne delivery of hemoglobin. In: Chang T.M.S. (Ed). Blood Substitutes 2 (1998), Karger, Basel 197-215
143. Szebeni J., Wassef N.M., Rudolph A.S., and Alving CR. Complement activation in human serum by liposome-encapsulated hemoglobin: the role of natural anti-phospholipid antibodies. Biochim Biophys Acta 1285 (1996) 127-130
144. Tsuchida E., Nishide H., and Ohno H. Liposome/heme as a totally synthetic oxygen carrier. Biomater Artif Cell Artif Organ 16 (1988) 313-319
145. Tsuchida E., and Nishide H. Synthesis and characterization of artificial red cell (ARC). Biomater Artif Cell Immobil Biotechnol 20 (1992) 337-354
146. Tsuchida E. Stabilized hemoglobin vesicles. Artif Cell Blood Subst Immobil Biotechnol Int J 22 (1994) 467-479
147. Takeoka S., Ohgushi T., Sakai H., Kose T., Nishide H., and Tsuchida E. Construction of artificial methe-moglobin reduction systems in Hb vesicles. Artif Cell Blood Subst Immobil Biotechnol Int J 25 (1997) 31-42
148. Sakai H., Hamada K., Takeoeka S., Nishide H., and Tsuchida E. Physical properties of hemoglobin vesicles as red cell substitutes. Biotechnol Prog 12 (1996) 119-125
149. Domokos G., Jopski B., and Schmidt KH. Prepration, properties and biological function of liposome encapsulate d hemoglobin. J Biomater Artif Cell Immobil Biotechnol 20 (1992) 345-354
150. Ogata Y, Goto H, Kimura T, Fukui H.Abstract volume for VI International Symposium on Blood Substitutes. Artif Cell Blood Subst Immobil Biotechnol Int J 4(24) 1996:396.
151. Takahashi A. Characterization of neo red cells (NRCs), their function and safety in vivo tests. Artif Cell Blood Subst Immobil Biotechnol Int J 23 (1995) 347-354
152. Takaori M., and Fukui A. Treatment of massive hemorrhage with liposome encapsulated human hemoglobin (NRC) and hydroxyethyl starch (HES) in beagles. Artif Cell Blood Subst Immobil Biotechnol Int J 24 (1996) 643-653
153. Usuba A., Motoki R., Ogata Y., Suzuki K., and Kamitani T. Effect and safety of liposome encapsulated hemoglobin "neo red cells (NRC)" as a perfusate for total cardiopulmonary bypass. Artif Cell Blood Subst Immobil Biotechnol Int J 23 (1995) 337-346
154. Chang TMS. Biodegradable semipermeable microcapsules containing enzymes, hormones, vaccines, and other biologicals. J Bioeng 1 (1976) 25-32
155. Chang TMS, Yu WP. Biodegradable Polymer Membrane Containing Hemoglobin as Potential Blood Substitutes. British Provisional Patent No. 92194265, Issued September 14, 1992.
156. Yu W.P., and Chang TMS. Submicron biodegradable polymer membrane hemoglobin nanocapsules as potential blood substitutes: A preliminary report. Artif Cell Blood Subst Immobil Biotechnol Int J 22 (1994) 889-894
157. Yu W.P., and Chang TMS. Submicron biodegradable polymer membrane hemoglobin nanocapsules as potential blood substitutes: Preparation and characterization. Artif Cell Blood Subst Immobil Biotechnol Int J 24 (1996) 169-184
158. Chang TMS, Yu WP. Biodegradable Polymer Membrane Containing Hemoglobin for Blood Substitutes. USA Patent 5670173, 1997.
159. Chang TMS. Artificial cell including blood substitutes and biomicroencapsulation: from ideas to applications. Artif Cell Blood Subst Immbol Biotechnol 22 (1994) vii-xiv
160. Chang TMS. Artificial cells. In: Dulbecco R. (Ed). Encyclopedia of Human Biology 1 (1991), Academic Press, Inc., San Diego, CA 377-383
161. Chang TMS. Artificial cells with emphasis on bioencapsuolation in biotechnology. Biotechnol Ann Rev 1 (1995) 267-296
162. Prakash S., and Chang TMS. Microencapsulated genetically engineered live E. coli DH5 cells administered orally to maintain normal plasma urea level in uremic rats. Nature Med 2 (1996) 883-887